Purpose: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections.

Design: Database study.

Participants: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0.54 logarithm of the minimum angle of resolution (logMAR) (±0.39). A total of 456 of these patients (270 female, 508 eyes, average age: 74.2 years) had sufficient follow-up data to be included for a 12-month VA prediction. The baseline VA before the first injection was 0.56 logMAR (±0.42).

Methods: Five different machine-learning algorithms (AdaBoost.R2, Gradient Boosting, Random Forests, Extremely Randomized Trees, and Lasso) were used to predict VA in patients with neovascular AMD after treatment with 3 anti-VEGF injections. Clinical data features came from a data warehouse (DW) containing electronic medical records (41 features, e.g., VA) and measurement features from OCT (124 features, e.g., central retinal thickness). The VA of patient eyes excluded from machine learning was predicted and compared with the ground truth, namely, the actual VA of these patients as recorded in the DW.

Main Outcome Measures: Difference in logMAR VA after 3 and 12 months upload phase between prediction and ground truth as defined.

Results: For the 3-month VA forecast, the difference between the prediction and ground truth was between 0.11 logMAR (5.5 letters) mean absolute error (MAE)/0.14 logMAR (7 letters) root mean square error (RMSE) and 0.18 logMAR (9 letters) MAE/0.2 logMAR (10 letters) RMSE. For the 12-month VA forecast, the difference between the prediction and ground truth was between 0.16 logMAR (8 letters) MAE/0.2 logMAR (10 letters) RMSE and 0.22 logMAR (11 letters) MAE/0.26 logMAR (13 letters) RMSE. The best performing algorithm was the Lasso protocol.

Conclusions: Machine learning allowed VA to be predicted for 3 months with a comparable result to VA measurement reliability. For a forecast after 12 months of therapy, VA prediction may help to encourage patients adhering to intravitreal therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ophtha.2017.12.034DOI Listing

Publication Analysis

Top Keywords

logmar letters
32
machine learning
16
ground truth
16
prediction ground
12
letters rmse
12
logmar
11
visual acuity
8
neovascular age-related
8
age-related macular
8
macular degeneration
8

Similar Publications

Purpose: To evaluate the efficacy of the dexamethasone implant on the electrophysiological profile of Diabetic Macular Oedema (DMO) patients over six months.

Methods: In this prospective, single-center study 30 eyes of 22 patients were examined using comprehensive baseline assessments including best-corrected visual acuity (BCVA), central retinal thickness (CRT), contrast sensitivity (CS) and multifocal electroretinogram (mfERG), before and after 0.7mg dexamethasone implant injection, with follow-ups at months 1, 2, 4, and 6.

View Article and Find Full Text PDF
Article Synopsis
  • A 16-year-old female experienced blurred vision in her left eye and was diagnosed with possible multiple evanescent white dot syndrome (MEWDS) secondary to acute retinal pigment epitheliitis (ARPE) after evaluation at the ophthalmology department.
  • Initial tests showed significant differences in visual acuity between her eyes, with abnormalities in retinal structure identified through imaging techniques like optical coherence tomography (OCT) and fundus autofluorescence (FAF).
  • After a two-week period with no treatment, her visual acuity improved and retinal abnormalities resolved, but there was an increase in white spots observed, indicating the complex nature of the two conditions—ARPE and MEWDS—making them potentially difficult to differentiate.
View Article and Find Full Text PDF
Article Synopsis
  • * A total of 66 eyes from 62 patients were evaluated, showing improvements in best corrected visual acuity and reductions in central macular thickness and retinal fluid after treatment with Faricimab.
  • * The results indicate that three loading doses of Faricimab are both effective, leading to significant visual and anatomical improvements, and safe, with only one minor adverse event reported.
View Article and Find Full Text PDF

Purpose: To determine long-term efficacy and safety of an extended macular vision intraocular lens (IOL) implanted in patients with dry age-related macular degeneration (AMD) and visually insignificant cataracts.

Design: Retrospective observational case series.

Setting: MicroChirurgia Oculare, Italy.

View Article and Find Full Text PDF

Objectives: To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.

Methods: Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!